These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
26. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Gargett T; Brown MP Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334 [TBL] [Abstract][Full Text] [Related]
27. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138 [TBL] [Abstract][Full Text] [Related]
28. Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma. Kintz H; Nylen E; Barber A Cell Immunol; 2020 May; 351():104069. PubMed ID: 32106933 [TBL] [Abstract][Full Text] [Related]
29. OX40 signaling is involved in the autoactivation of CD4 Jiang J; Liu C; Liu M; Shen Y; Hu X; Wang Q; Wu J; Wu M; Fang Q; Zhang X Arthritis Res Ther; 2017 Mar; 19(1):67. PubMed ID: 28320444 [TBL] [Abstract][Full Text] [Related]
30. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295 [TBL] [Abstract][Full Text] [Related]
31. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Ohshima Y; Yang LP; Uchiyama T; Tanaka Y; Baum P; Sergerie M; Hermann P; Delespesse G Blood; 1998 Nov; 92(9):3338-45. PubMed ID: 9787171 [TBL] [Abstract][Full Text] [Related]
32. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. Savoldo B; Ramos CA; Liu E; Mims MP; Keating MJ; Carrum G; Kamble RT; Bollard CM; Gee AP; Mei Z; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Dotti G J Clin Invest; 2011 May; 121(5):1822-6. PubMed ID: 21540550 [TBL] [Abstract][Full Text] [Related]
33. Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell. Taheri FH; Hassani M; Sharifzadeh Z; Behdani M; Abdoli S; Sayadi M; Bagherzadeh K; Arashkia A; Abolhassani M BMC Biotechnol; 2024 Jan; 24(1):1. PubMed ID: 38178096 [TBL] [Abstract][Full Text] [Related]
34. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. Janardhan SV; Praveen K; Marks R; Gajewski TF PLoS One; 2011; 6(9):e24931. PubMed ID: 21949793 [TBL] [Abstract][Full Text] [Related]
35. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050 [TBL] [Abstract][Full Text] [Related]
36. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells. Mezősi-Csaplár M; Szöőr Á; Vereb G Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370693 [TBL] [Abstract][Full Text] [Related]
37. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959 [TBL] [Abstract][Full Text] [Related]
38. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers. Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017 [TBL] [Abstract][Full Text] [Related]
39. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063 [TBL] [Abstract][Full Text] [Related]
40. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Levine BL; Ueda Y; Craighead N; Huang ML; June CH Int Immunol; 1995 Jun; 7(6):891-904. PubMed ID: 7577797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]